Kenox Pharmaceuticals Expands Capabilities to Strengthen Drug Development Offerings

by

KENOX Pharmaceuticals

KENOX Pharmaceuticals

Kenox Pharmaceuticals Inc. (Kenox), a leading innovator in Orally Inhaled and Nasal Drug Products (OINDPs), has expanded its capabilities to support GLP pre-clinical studies with small-scale non-sterile GMP manufacturing. This strategic growth strengthens Kenox’s drug development services, helping pharmaceutical companies bring inhaled and nasal therapies to market faster.

With the addition of a cleanroom for compounding, fill-finish, and release of non-sterile nasal sprays and dry powders, Kenox enhances its ability to provide end-to-end solutions. The company is also expanding further to introduce small-scale GMP batch manufacturing for Phase I and II clinical trials, covering both non-sterile and sterile OINDPs.

By integrating these new capabilities, Kenox streamlines early-stage drug development, reducing risk and offering a comprehensive, one-stop solution from molecule to clinic. This expansion underscores Kenox’s commitment to advancing pharmaceutical innovation and supporting companies in developing life-changing inhaled and nasal therapies.

“I’m so excited about this expansion which was executed in a timely manner. This would not have been possible without our talented and capable team, rockstar QA, support from our partners/clients, various vendors, and the facility management,” said Sitaram Velaga, Founder, President and CEO at Kenox Pharmaceuticals Inc. “This expansion reflects our dedication to support our partners in their mission to develop cutting edge therapeutics for unmet medical needs with meticulous attention to quality, efficiency, project goals, and timelines.”

With these new capabilities, Kenox Pharmaceuticals Inc is well poised to support a diverse range of OINDP dosage forms intended for different therapeutic areas including but not limited to cardiology, psychiatry, antimicrobial/antiviral, pain management and rare diseases. Together with its proven track record and thorough understanding of formulation design, pre-clinical and clinical manufacturing and regulator support, Kenox offers a true high quality end-to-end solution for biopharmaceutical innovators. Due to its unique flexibility and scalability, Kenox can serve partners/clients from start-up companies to big pharma equally well.

About Kenox

Established in 2018 and based out in greater Princeton, NJ, Kenox specializes in pharmaceutical aerosol product development including soft mist inhalers (SMIs), pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), nebulizers, nasal sprays and ophthalmic products. As a contract development organization, Kenox offers a wealth of expertise with regards to formulation design, compounding, fill-finish and testing in compliance with compendial monographs.

Kenox Pharmaceuticals, Inc. Website

Source – Kenox Pharmaceuticals:
Kenox Pharmaceuticals, Inc. Website

News from Cleanroom Connect